Curocell

Curocell Inc. is a cell and gene therapy development company engaged in the development and manufacturing of pharmaceuticals. It provides research and development services and offers OVercome Immune Suppression (OVIS), a proprietary platform technology designed to overcome exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Founded in 2016, Curocell Inc. is headquartered in Daejeon, South Korea.